Fortrea (FTRE): Buy, Sell, or Hold Post Q2 Earnings?

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

FTRE Cover Image

Fortrea has been on fire lately. In the past six months alone, the company’s stock price has rocketed 77%, reaching $18.31 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Is now the time to buy Fortrea, or should you be careful about including it in your portfolio? Get the full stock story straight from our expert analysts, it’s free.

Why Do We Think Fortrea Will Underperform?

We’re happy investors have made money, but we’re cautious about Fortrea. Here are three reasons you should be careful with FTRE, plus one stock we’d rather own.

1. Revenue Spiraling Downwards

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, Fortrea’s demand was weak and its revenue declined by 3% per year. This wasn’t a great result and signals it’s a low quality business.

Fortrea Quarterly Revenue

2. Previous Growth Initiatives Have Lost Money

Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

Fortrea’s five-year average ROIC was negative 8.5%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector.

Fortrea Trailing 12-Month Return On Invested Capital

3. New Investments Fail to Bear Fruit as ROIC Declines

ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

Unfortunately, Fortrea’s ROIC has decreased significantly over the last few years. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Fortrea Trailing 12-Month Return On Invested Capital

Final Judgment

Fortrea falls short of our quality standards. After the recent rally, the stock trades at 19.6× forward P/E (or $18.31 per share). This valuation tells us it’s a bit of a market darling with a lot of good news priced in - we think other companies feature superior fundamentals at the moment. Let us point you toward the most entrenched endpoint security platform on the market.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article